Literature DB >> 19760670

Lymphadenectomy for patients with cervical cancer: is it of value?

Peter J Rossi1, Ira R Horowitz, Peter A S Johnstone, Ashesh B Jani.   

Abstract

INTRODUCTION: Discovery of positive lymph nodes (LNs) in patients with cervix cancer is important prognostically, may direct adjuvant therapy, and may have therapeutic benefit. The purpose of this Surveillance Epidemiology and End Results (SEER) analysis was to assess the value of lymphadenectomy (LND) in patients with cervical cancer.
METHODS: The 17-registry SEER database was searched for patients treated for cervical cancer between 1988 and 1998. Observed survival (OS) and expected survival (ES) were reported with a minimum of 5-year follow-up. Chi-square analysis and log-rank test were used to compare OS and ES.
RESULTS: Between 1988 and 1998, 4,059 of 12,882 patients underwent LND for cervical cancer and were registered. By stage, 2,653 of 7,621 stage I, 341 of 2,042 stage II, 814 of 1,986 stage III, 251 of 1,233 stage IV, and 28 of 226 stage IVA patients underwent LND. Of these, 778 stage III and 210 stage IV patients had a +LN. Patients who underwent LND had improved OS (P = 0.001). OS was significantly increased for each stage after LND. OS increased based on number of nodes resected. OS increased up to 15 nodes resected (P = 0.01).
CONCLUSION: This SEER analysis of 12,882 patients suggests that LND benefited patients with cervical cancer and OS was improved. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19760670     DOI: 10.1002/jso.21330

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  How important is the number of pelvic lymph node retrieved to locorregional staging of cervix cancer?

Authors:  Thales Paulo Batista; Artur Lício Rocha Bezerra; Mário Rino Martins; Vandré Cabral Gomes Carneiro
Journal:  Einstein (Sao Paulo)       Date:  2013-12

2.  Development and validation of a surgical-pathologic staging and scoring system for cervical cancer.

Authors:  Shuang Li; Xiong Li; Yuan Zhang; Hang Zhou; Fangxu Tang; Yao Jia; Ting Hu; Haiying Sun; Ru Yang; Yile Chen; Xiaodong Cheng; Weiguo Lv; Li Wu; Jin Zhou; Shaoshuai Wang; Kecheng Huang; Lin Wang; Yuan Yao; Qifeng Yang; Xingsheng Yang; Qinghua Zhang; Xiaobing Han; Zhongqiu Lin; Hui Xing; Pengpeng Qu; Hongbing Cai; Xiaojie Song; Xiaoyu Tian; Jian Shen; Ling Xi; Kezhen Li; Dongrui Deng; Hui Wang; Changyu Wang; Mingfu Wu; Tao Zhu; Gang Chen; Qinglei Gao; Shixuan Wang; Junbo Hu; Beihua Kong; Xing Xie; Ding Ma
Journal:  Oncotarget       Date:  2016-04-12

3.  Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer.

Authors:  Zhilan Chen; Yingyan Han; Chengwen Song; Huafang Wei; Ying Chen; Kecheng Huang; Shuang Li; Ding Ma; Shixuan Wang; Jing Wang; Qiping Lu
Journal:  Oncotarget       Date:  2017-12-16

4.  Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer.

Authors:  Masaru Wakatsuki; Tatsuya Ohno; Shingo Kato; Ken Ando; Shin-Ei Noda; Hiroki Kiyohara; Kei Shibuya; Kumiko Karasawa; Tadashi Kamada; Takashi Nakano
Journal:  J Radiat Res       Date:  2013-08-02       Impact factor: 2.724

5.  Prognostic significance of lymph node ratio in node-positive cervical cancer patients.

Authors:  Ji Hyeon Joo; Young Seok Kim; Joo-Hyun Nam
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy.

Authors:  Jinju Oh; Ki Ho Seol; Youn Seok Choi; Jeong Won Lee; Jin Young Bae
Journal:  Yeungnam Univ J Med       Date:  2019-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.